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INTRODUCTION
Studies have shown that genetic polymorphism
(rs12979860) near the interferon-lambda-3 (IFNλ3)
gene, on chromosome-19, formally known as interleukin
28B, is associated with variable responses to the
pegylated interferon (Peg-IFN). The CC-genotype of
IFNλ3 is associated with two to three fold increase in
sustained virologic response (SVR) as compared with
either CT or TT genotype in patients infected with
hepatitis-C virus (HCV) genotype-1.1,2
A landmark study published in Nature-1, analyzed the
data of more than 1,600 patients infected with HCV
genotype-1 enrolled in another clinical trial.3 SVR rates
in patients with the CC-genotype of rs12979860 IFNλ3
were 69% in Caucasians, 48% in African-Americans,
and 56% in Hispanics. For each group, these response
rates were substantially higher (two folds) than for two
other genotypes, TC and TT. Overall, the adjusted odds
ratio for SVR associated with CC versus the other
genotypes was 5.2 (95%; CI 4.1 to 6.7), the largest odds
ratio of any pre-treatment predictor. The rs12979860-C
variant is most frequently present in individuals from
East Asia (allele frequency > 0.9) and least common in
individuals of African origin (allele frequency 0.2 - 0.5).4
In a US based study, the favourable CC genotype was
observed in 37% of Caucasians, 29% of Hispanics, and
14% of African Americans tested.2
Though HCV genotype-3 (HCV-3) was considered as an
'easy-to-treat' virus with pegylated interferon (Peg-IFN)
and ribavirin, the assumption was based on the initial
studies that analyzed the combined data of genotype-2
and 3.5 However, SVR rates appear to be lower in
certain subgroups of people infected with HCV-3
compared with those with HCV-2. There are few
available data regarding the association between IFNλ3
rs12979860 polymorphism and SVR to Peg-IFN plus
ribavirin therapy in HCV-3 patients in Pakistani
population.
The aim of this study was to find out frequency of IFNλ3
rs12979860 CC, TC and TT genotypes in patients
infected with HCV-3, with SVR, non-response or relapse
to the Peg-IFN and ribavirin therapy.
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ABSTRACT
Objective: To assess the role of single nucleotide polymorphisms (SNPs) near the interferon lambda-3 (IFNλ3) (formal
IL-28B) gene rs12979860 in predicting sustained virologic response (SVR) in hepatitis-C virus genotype-3 (HCV-3).
Study Design: Descriptive, analytical study.
Place and Duration of Study: Department of Medicine, The Aga Khan University Hospital, Karachi, from July 2012 to
June 2014.
Methodology: Patients with HCV-3 were classified as sustained virologic response (SVR), relapsers and non-responders.
SNP rs12979860 was determined by PCR-RFLP protocol. Differences between categorical variables were assessed by
chi-square or Fisher's exact test, while those between continuous variables were evaluated using the Mann-Whitney
U-test. Binary logistic regression analysis by forward conditional method was performed by using significant variables with
p-values less than 0.05 as the criteria for model inclusion.
Results: Out of 115 patients, rs12979860 genotype-CC, CT, TT was found in 37 (32.2%), 70 (60.9%), and 8 (7%) patients.
72 patients were male with median age of 45 years. Cirrhosis was present in 32 patients. Patients with response failures
(no response and relapse, n=36 and 29, respectively) had higher baseline gamma glutamyl transferase (GGT) level
(p < 0.001), higher alanine aminotransferase (p=0.027) and cirrhosis (p=0.001) than patients with SVR. Genotype-CC was
present in 16/65 in response failures compared to 21/50 who achieved SVR (p=0.048). Rapid virologic response (RVR)
(p < 0.001), low GGT (p=0.001) and absence of cirrhosis (p=0.039) were the independent predictive factors for SVR. In
patients who could not achieve RVR and in patients with cirrhosis, SVR was seen more in with genotype-CC (p=0.007
and 0.038).
Conclusion: In patients infected with HCV-3, IFNλ3 rs12979860, SNP has less impact on SVR.
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METHODOLOGY
The study was conducted at the Department of
Medicine, The Aga Khan University Hospital, Karachi,
from July 2012 to June 2014.
Study population included HCV-3 patients who were
treated with peg-IFN and ribavirin with compensated
liver disease for whom longitudinal observations were
available from the medical records. Patients were
considered to have chronic hepatitis-C when HCV-RNA
was detectable in patients reactive for anti-HCV
antibodies for more than 6 months. Patients were
categorized as responders, non-responders, and
relapsers to the therapy. Exclusion criteria were previous
treatment with standard or Peg-IFN, duration of
treatment less than laid down criteria for response
guided therapy, co-infection with hepatitis-B or HIV,
decompensated cirrhosis, alcohol abuse, autoimmune
disorders or hepatocellular carcinoma. Patients were
also excluded when end-of-treatment and follow-up
HCV RNA status was not documented.
The duration of treatment was 6 months for patients who
had a rapid virologic response (RVR), i.e. clearance of
the virus from the blood at 4 weeks of therapy, and 48
weeks who could not achieve RVR but had an early
virologic response (EVR), i.e. negative serum HCV RNA
at 12 weeks of therapy. Responders were the patients
who had negative HCV RNA at the end of treatment and
6 months post-treatment (SVR). Patients who could not
clear the virus at 12 weeks of treatment were considered
as non-responders. Relapsers had end of treatment
virologic response (ETR) but no SVR.
The study was approved by the Ethics Committee of the
hospital. Informed consent was obtained from each
patient. Baseline characteristics at the time of
commencement of therapy were noted from the records,
including age, gender, body mass index (BMI), HBsAg
status, HCV RNA, qualitative or quantitative, and
genotype and duration of therapy received. Blood
samples were taken for HCV RNA and SNP. SNP of
IFNλ3 rs12979860 was determined by polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) protocol as mentioned below. HCV RNA
clearance was compared in lambda-3 rs12979860 “CC”
with “non CC”.
Seven ml blood was drawn into ethylene diamine tetra
acetic acid (EDTA) tube. Genotyping for the IL-28B
rs12979860 C/T polymorphism was performed by
polymerase chain reaction based restriction fragment
length polymorphism assay. Genomic DNA was
extracted from whole blood samples by means of the
QIA amp DNA blood mini-kit (Qiagen, Milan, Italy)
according to manufacturer's instruction. A 242 base
pair (bp) product was obtained with the forward
primer 5’-GCTTATCGCATACGGCTAGG-3’ and the
reverse primer 5’-AGGCTCAGGGTCAATCACAG-3’, as
previously described.6 PCR amplification was carried
out in a total volume of 10 µl containing 10 mM Tris-HCl
(pH 8.3), 50 mM KCl, Tween-20 0.01%, 0.2 mM
deoxyribonucleotides, 2-4 pmol of each primer, 2.0 mM
MgCl2, and 0.5 units hot-start Taq DNA polymerase
(Promega, Madison, WI, USA). Samples containing 10
ng of genomic DNA were subjected to 40 cycles of
denaturation (at 95°C for 30 seconds), annealing (at
62°C for 30 seconds), and elongation (at 72°C for 30
seconds) using a Perkin Elmer 9700 thermal cycler. In a
total volume of 20 µl, 10 µl of the amplified products
were digested with 1 unit of the Bst U-I restriction
endonuclease (New England Bioloabs, Hitchin, UK) at
60°C overnight. The fragments digested were,
respectively, 135 + 82 + 25 bp for the C allele and
160 + 82 bp for the T-allele variant. The fragments were
resolved by electrophoresis in 3.5% agarose gel after
staining with ethidium bromide. In 5 patients, the
genomic region encompassing the IL-28B rs12979860
C/T polymorphism was sequenced with results
confirming those obtained by the RFLP assay.
Serum HCV-RNA levels were quantified with the Real
Time PCR COBAS AmpliPrep/COBAS TaqMan HCV
Test 2.0 (Roche Molecular Systems, NJ, USA). The
reverse transcription reaction (RT) was performed using
first strand M-MLV reverse transcriptase kit (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer's
instructions. Briefly, 5 µl out of the extracted RNA was
added to 15 µl of RT mixture containing RT buffer, dNTP
mix (10 mM each of four deoxynucleoside triphosphate
stocks), 50 µM random hexamer primer and 75 U of M-
MLV reverse transcriptase. The RT reaction mixture was
incubated at 37°C for 120 minutes, and then at 85°C for
5 minutes to inactivate the enzyme. The resulting 20 µl
of cDNA was kept at -20°C until use.
Statistical analyses were performed using SPSS,
release 20 (IBM Corporation, Chicago, IL, USA).
Categorical variables were expressed as frequencies
(%) while continuous variables were presented as
median with 25th-75th percentiles inter-quartile range
(IQR). Differences between categorical variables were
assessed by chi-square or Fisher's exact test, while
those between continuous variables were evaluated
using the Mann-Whitney U-test. Binary logistic
regression analysis by forward conditional method was
performed by using significant variables with p-values
less than 0.05 as the criteria for model inclusion. For this
model, continuous variables were converted into
dichotomous variables using median values as cut off.
RESULTS
Out of 115 patients, 72 (62.3%) were male. Mean age
was 43.4 ±10.4 years, median 45 years ranging from
18 - 67 years and interquartile range (IQR) of 36.0-50.0.
Median body mass index (BMI) was 26.2 (IQR: 23.5-
29.6), alanine aminotransferase (ALT) 67 (IQR: 44-101),
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gamma glutamyl transferase (GGT) 51 (IQR: 32-83).
Baseline quantitative HCV RNA levels were available
only in 43 patients; median 7.84 x 105 (IQR: 2.11 x 105 -
2.91 x 106). Twenty-seven (23.5%) patients were
diabetic. Cirrhosis of the liver as evident from histology,
ultrasound or clinical examination was present in 32
(27.8%) patients. Patients with SVR were 50 (43.5%),
non-responders 36 (31.3%), and relapses 29 (25.2%).
IFNλ3 rs12979860 genotype CC, CT, TT was found in
37 (32.2%), 70 (60.9%), and 8 (7%) of patients. In
carriers of rs12979860 genotype CC, SVR, relapse and
non-response was seen in 21 (56.8%), 7 (18.9%), and 9
(24.3%) patients. These figures were 24 (34.3%), 21
(30.0%), and 25 (35.7%) for genotype CT; and 5 (62.5%),
1 (12.4%), 2 (25%) for genotype TT, respectively. Rapid
virologic response (RVR) was not associated with IFNλ3
rs12979860 genotype as it was seen in 21/37 of CC
genotype and 40/78 of non-CC genotype (p=0.583).
RVR was linked with absence of clinical cirrhosis;
achieved in 51/83 (61%) patients without cirrhosis
versus 10/32 (31%) with cirrhosis (p=0.004). However, in
patients who could not achieve RVR, SVR was seen
more in patients with genotype CC; 5/16 (31%) patients
with genotype CC compared to 1/37 (3%) patients with
non-CC (p=0.007). There was no signigicant association
of the presence of clinical cirrhosis with rs12979860
genotype (p=0. 564). Nevertheless, in patients with
cirrhosis (n=32), SVR was achieved in 4/6 patients with
genotype CC, compared with 5/26 with non-CC
genotype (p=0.038).
There was no difference in the age, BMI, and HCV RNA
level among patients with SVR and response failures
(non-response, or relapse) to the treatment (Table I).
The median GGT of response failures was higher than
responders (p < 0.001). They had higher ALT levels
(p=0.027) and cirrhosis (p=0.001). Genotype CC was
present in 16/65 (25%) response failure patients
compared to 21/50 (42%) who achieved SVR (p=0.048).
Logistic regression analysis showed that RVR
(p < 0.001), low GGT (p=0.001) and absence of clinical
cirrhosis (p=0.039) were the independent factors to have
a SVR.
DISCUSSION
Host genetics play an indispensable part in the ability
not only to clear acute hepatitis-C infection, but likewise
Table I: Characteristics of patients who received pegylated interferon plus ribavirin therapy.
Sustained responders Non-responders and relapsers p-value Odds ratio 95% Conf. Interval
n=50 n=65
Gender
Male 33 (66%) 39 (60%) 0.510 1.29 0.56-3.00
Female 17 (34%) 26 (40%)
Age (years)
Median (IQR) 42 (32-50) 45 (37-50) 0.199
Age < 45 28 (56%) 26 (40%) 0.088 1.91 0.85-4.32
Body mass index (kg/m2)
Median (IQR) 26.4 (23.5-29.0) 26.2 (23.8-29.2) 0.772
BMI up to 26 kg/m2 22 (44%) 28 (43%) 0.921 1.04 0.46-2.34
Absence of diabetes 41 (82%) 47 (72%) 0.224 1.75 0.65-4.75
Absence of cirrhosis 44 (88%) 39 (60%) 0.001* 4.89 1.68-14.89
ALT (IU/L)
Median (IQR) 60 (39-91) 71 (47.5-114.5) 0.027
ALT ≤ 67 29 (58%) 29 (45%) 0.155 1.71 0.76-3.87
GGT (IU/L)
Median (IQR) 34 (27-54.3) 70 (44-121) <.001*
GGT ≤ 51 37 (74%) 21 (32%) <.001* 5.96 2.45-14.78
Interferon λ3 type
CC 21 (42%) 16 (25%) 0.048* 2.22 0.93-5.32
Non-CC 29 (58%) 49 (75%)
Rapid virologic response 44 (88%) 17 (26%) <.001* 20.71 6.85-65.99
P-values by Fisher exact test / chi-square teat or Man-Whitney U test. *statistically significant p-values S.D.: standard deviation; IQR: interquartile range; ALT: Alanine aminotransferase;
GGT: Gamma glutamyl transferase.
Figure 1: IFNλ3 rs12979860, CC or non-CC genotypes, and response to
pegylated interferon in patients with hepatitis D
ETR = End of treatment virologic response; SVR = Sustained virologic response.
to achieve sustained virologic response (SVR) to
interferon. In a study, carriers of the IFNλ3 rs12979860
C-allele who responded to interferon therapy, exhibited
increased IFN-lambda levels.7 Moreover, high IFN-
lambda levels pre-disposed to spontaneous resolution of
HCV infection. Thus, IFN-lambdas seem to play an
important role in the control of hepatitis-C.
The role of IFNλ3 polymorphism in predicting response
to interferon alpha based treatment in case of genotype 3
is debatable.8-12 Nevertheless, a recent adequately
powered study demonstrated that IFNλ3 genotypes are
strong baseline predictors of SVR.10 The writers
concluded that confounders including cohort size
explained to a great degree the controversy from
previous stories. When the sample size is decent, the
association between IL-28B and RVR or SVR can be
appreciated in HCV-3.11 Thus, it may be rational to
evaluate IFNλ3 genotyping in patients with HCV-3
infection. Apparently the predictive value of rs12979860
CC in case of HCV-3 is less strong requiring a bigger
sample size to become an independent predictor. This
study of 115 patients indicates that rs12979860 SNP
associates with SVR in HCV-3 infected patients.
However, this variable got dropped during the regression
analysis.
Distribution of rs12979860 genotypes in our general
population is not known. In a study from Thailand, the
distribution of IFNλ3, rs12979860 CC, CT, and TT in
hepatitis-C patients of all viral genotypes was 84%,
12.4% and 3.6%, respectively.8 In this study of HCV-3
patients, rs12979860 CC/CT/TT was found in 32.2%,
60.9% and 7% patients. Significantly lower frequencies
of the favourable genotypes CC in these HCV-3 patients
may be due to lower frequency of this genotype in the
studied population or significant number of individuals
with this genotype spontaneously clear the virus.
IFNλ3 genotype CC-genotype patients respond more
promptly to treatment compared with the CT and TT
genotypes in case of infection with HCV genotype-1.
Moreover, CC genotype also predicted SVR in
Caucasian patients who did not have RVR (66% vs. 31%
and 24% respectively).2 In this study done on
genotype-3 patients, there was no difference in the RVR
between genotype CC and non-CC. RVR was
associated with absence of clinical cirrhosis (p-0.004).
However, in patients who could not achieve RVR, SVR
was seen in 5/16 patients with genotype-CC compared
to 1/37 patients with non-CC (p=0.007). Other workers
have also observed stronger impact of this
polymorphism in this sub-set of patients.13
Few data are available about the value of IFNλ3
polymorphism in predicting SVR in patients with
cirrhosis. Bruno et al. could not find its association with
the clinical outcome in patients with HCV-3 induced
compensated cirrhosis.14 In this study, clinical cirrhosis
was present in 32 patients. SVR was less in patients
with cirrhosis (p=0.001). SVR was achieved in 4/6
patients with genotype-CC, compared with 5/26 with
non-CC genotype (p=0.038). But the number is too small
and a larger study needed to accept or refute the role of
this SNP in HCV-3 cirrhotic patients. So SVR appears to
be lower in certain sub-groups of people infected with
HCV-3 where the predictive value of IFNλ3 genotypes
increases.
Suppiah et al. and Tanaka et al. identified a second
polymorphism (rs8099917) in a similar region near the
IL-28 gene, which was strongly linked with response to
combination treatment with interferon and ribavirin in
Australian and Japanese patients, all infected with viral
genotype-1.15,16 Higher rates of SVR are associated with
rs8099917 TT-genotype.17 Rauch et al. conducted a
genome-wide association study (GWAS) including all
viral genotypes 1-4, and found that the rs8099917 minor
allele was linked with both progression in chronic
hepatitis-C and failure to respond to treatment, with the
most potent effects in patients infected with genotypes-1
or 4.18 The gene polymorphsion rs8099917 was tested
in only 25 patients. Its TT, TG and GG genotypes were
in concordance with rs12979860 CC, CT and TT in all,
except in 2 cases. Due to its strong correlation with
rs12979860 in IL-28B, we thought there would not be
any added benefit of testing this polymorphism in our
patients. Similar correlation was found in another study
done in patients of French ancestry in Canada.19 These
patients were not tested for IFN lambda-4. This
polymorphism has been investigated as predictor of
SVR in genotype-3 infected patients with conflicting
results,20,21 and testing for the SNP in this region as
treatment predictor in Caucasian patients also does not
offer any special advantage.20
Despite the availability of direct acting anti-viral drugs
interferon based regimens will remain in the
armamentarium for patients with HCV-3, due to non-
availability and exuberant cost of DAAs or in
combination with DAAs to achieve a better response
rate. So the IFNλ3 SNP status in these patients may
facilitate in decision-making for these patients. Though a
meta-analysis failed to measure the impact of the IFNλ3
SNP in HCV-3 treatment outcome,22 the bearing of the
favourable genotypes-CC may be one of the pre-
treatment predictors of the effectiveness of interferon
based therapy in difficult-to-treat-patients infected with
HCV-3.
CONCLUSION
Genetic analysis for IFNλ3 rs12979860 is only one of
many factors that can influence response rates to
pegylated interferon and ribavirin therapy in HCV-3
infection and should be interpreted in the context of
other clinical factors predicting SVR including advanced
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fibrosis and cirrhosis. IFNλ3 genotyping can aid in
clinical decision-making for patients with HCV-3 who
have cirrhosis or could not achieve RVR infection.
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